Concepedia

Yuchen Bai

YB

13

Publications

1.8K

Citations

12

H-Index

2005

Active since

Affiliations

GlaxoSmithKline (United States)(Current)

University of Ulster

Peter MacCallum Cancer Centre

Institute of Molecular and Cell Biology

University of Macau

Yuchen Bai is an author at GlaxoSmithKline (United States) specializing in medicine, tumor biology, and cancer research.

Top concepts

MedicineTumor BiologyCell BiologyCancer ResearchRadiation OncologyUrologyOncologyPharmacologyCancer BiologySystems Biology

Publications per year

2005–2023

13

Publications

13

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2015 · 501 citations · Full text

A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC

Helai P. Mohammad, Kimberly N. Smitheman, Chandrashekhar D. Kamat et al. · Cancer Cell · 2015 · 498 citations · Full text

Oncogenic Agent, Medicine, Epigenetic Change +9

BET Inhibition Silences Expression of MYCN and BCL2 and Induces Cytotoxicity in Neuroblastoma Tumor Models

Anastasia Wyce, Gopinath Ganji, Kimberly N. Smitheman et al. · PLoS ONE · 2013 · 203 citations · Full text

Mycn Copy Number, Bet Family Proteins, Cell Regulation +14

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

Anastasia Wyce, Yan Degenhardt, Yuchen Bai et al. · Oncotarget · 2013 · 176 citations · Full text

Over-express Myc, Bet Bromodomain Proteins, Urology +14

The prognostic significance of Cdc6 and Cdt1 in breast cancer

Ravikiran Mahadevappa, Henrique Neves, Shun Ming Yuen et al. · Scientific Reports · 2017 · 111 citations · Full text

Rows per page

1–5 of 13